Compare BIIB & NTAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIIB | NTAP |
|---|---|---|
| Founded | 1978 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electronic Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 22.2B |
| IPO Year | 1991 | 1995 |
| Metric | BIIB | NTAP |
|---|---|---|
| Price | $173.17 | $112.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 14 |
| Target Price | ★ $177.40 | $123.15 |
| AVG Volume (30 Days) | ★ 2.7M | 2.3M |
| Earning Date | 10-30-2025 | 11-25-2025 |
| Dividend Yield | N/A | ★ 1.86% |
| EPS Growth | N/A | ★ 5.78 |
| EPS | ★ 10.97 | 5.75 |
| Revenue | ★ $10,065,900,000.00 | $6,637,000,000.00 |
| Revenue This Year | $3.61 | $4.95 |
| Revenue Next Year | N/A | $4.87 |
| P/E Ratio | ★ $15.93 | $19.46 |
| Revenue Growth | ★ 4.77 | 2.53 |
| 52 Week Low | $110.04 | $71.84 |
| 52 Week High | $185.17 | $127.78 |
| Indicator | BIIB | NTAP |
|---|---|---|
| Relative Strength Index (RSI) | 53.21 | 46.34 |
| Support Level | $168.56 | $107.63 |
| Resistance Level | $175.94 | $114.73 |
| Average True Range (ATR) | 5.21 | 2.94 |
| MACD | -1.78 | -0.44 |
| Stochastic Oscillator | 34.76 | 36.97 |
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
NetApp Inc is a provider of enterprise data management and storage solutions. The company's segments include Hybrid Cloud and Public Cloud. It generates maximum revenue from the Hybrid Cloud segment. The Hybrid Cloud segment offers a portfolio of storage management and infrastructure solutions that help customers recast their traditional data centers with the power of the cloud. This portfolio is designed to operate with public clouds to unlock the potential of hybrid, multi-cloud operations. Hybrid Cloud is composed of software, hardware, and related support, as well as professional and other services. Geographically, the company generates the majority of its revenue from the United States, Canada and Latin America (Americas).